- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.01. | Prenetics divests 3PL distribution business in all-stock deal valued at up to $13M | 2 | Seeking Alpha | ||
| 05.01. | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.12.25 | David Beckham's Prenetics halts $1B Bitcoin plan to focus on IM8 health brand | 1 | iNVEZZ.com | ||
| 30.12.25 | Prenetics halts Bitcoin purchases to focus on consumer health brand, IM8 | 2 | Seeking Alpha | ||
| 30.12.25 | Prenetics Global Limited: Prenetics Announces Update to Capital Allocation Strategy; Ceases Bitcoin Purchases to Focus on IM8 | 217 | GlobeNewswire (Europe) | Company's Capital and Strategic Focus Now Exclusively Focused on IM8 IM8 FY 2026 Revenue Projected to Reach $180 - $200 Million CHARLOTTE, N.C., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Prenetics Global... ► Artikel lesen | |
| 23.12.25 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| PRENETICS GLOBAL Aktie jetzt für 0€ handeln | |||||
| 23.12.25 | Prenetics Global Limited: Prenetics Enters Into Warrant Exchange Agreements With Warrant Holders, Strengthening Capital Structure | 306 | GlobeNewswire (Europe) | CHARLOTTE, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and... ► Artikel lesen | |
| 11.12.25 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.11.25 | Prenetics executives purchase $1.4 million in company stock | 1 | Investing.com | ||
| 24.11.25 | Prenetics executives buy $1.45M in company stock | 2 | Seeking Alpha | ||
| 24.11.25 | Prenetics-Management investiert 1,45 Millionen US-Dollar in eigene Aktien | 1 | Investing.com Deutsch | ||
| 24.11.25 | Prenetics Global Limited: Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million | 2 | GlobeNewswire (USA) | ||
| 17.11.25 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.11.25 | Prenetics Global Limited: Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth | 426 | GlobeNewswire (Europe) | IM8's Strong Unit Economics-60% Margins and 3.9-Month Payback-Central to Cantor's Bullish Outlook Cantor Notes PRE's ~$120M Liquidity and 387 BTC Treasury as Strengthening the Company's Financial... ► Artikel lesen | |
| 12.11.25 | Cantor Fitzgerald lowers Prenetics stock price target to $31 on Q3 results | 2 | Investing.com | ||
| 10.11.25 | Prenetics Global GAAP EPS of -$0.53, revenue of $23.6M | 3 | Seeking Alpha | ||
| 10.11.25 | Prenetics Global Limited: Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR by December 2025, Fastest Supplement Brand Growth in Industry History | 236 | GlobeNewswire (Europe) | Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M... ► Artikel lesen | |
| 10.11.25 | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 07.11.25 | Prenetics Global's Earnings: A Preview | 1 | Benzinga.com | ||
| 04.11.25 | Prenetics' IM8 achieves record $9M in revenue for October | 3 | Seeking Alpha |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CANSINO BIOLOGICS | 3,676 | +0,49 % | CanSino Biologics Inc: Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle | HONG KONG, Aug 20, 2025 - (ACN Newswire) - In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades... ► Artikel lesen | |
| SINO BIOPHARM | 0,700 | -2,10 % | Aktienmarkt: Aktie von Sino Biopharmaceutical tritt auf der Stelle (0,88 €) | Wenig Kursbewegung zur Stunde bei der Sino Biopharmaceutical-Aktie . Das Wertpapier notiert aktuell bei 0,88 Euro. Ein geringes Minus von 5,12 Prozent zeigt die Kurstafel für die Aktie von Sino Biopharmaceutical... ► Artikel lesen | |
| GENSCRIPT BIOTECH | 1,281 | 0,00 % | GenScript USA: 'Scripting Possibilities' in Biotechnology: Global Innovators Converge in San Francisco for GenScript's 5th Annual Biotech Forum During JPM Week | PISCATAWAY, N.J., Jan. 6, 2026 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, is proud to announce its 5th Annual Biotech... ► Artikel lesen | |
| QUANTUM-SI | 1,060 | +13,72 % | Quantum-Si Inc - 8-K, Current Report | ||
| INNOVENT BIOLOGICS | 8,550 | -3,39 % | INNOVENT BIO (01801): INSIDE INFORMATION ANNOUNCEMENT - ROBUST GROWTH ACHIEVED IN PRODUCT REVENUE IN THE YEAR AND THE FOURTH QUARTER OF 2025 | ||
| SCILEX | 8,440 | +7,38 % | Scilex Holding Co - 8-K, Current Report | ||
| ORIGIN AGRITECH | 0,880 | -11,11 % | Origin Agritech LTD - 6-K, Report of foreign issuer | ||
| AKESO | 10,700 | -1,83 % | AKESO (09926): VOLUNTARY ANNOUNCEMENT - AKESO GRANTED EXCLUSIVE COMMERCIALIZATION RIGHTS FOR EBRONUCIMAB INJECTION TO JUMPCAN PHARMACEUTICAL | ||
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Ionos, Kontron, Lanxess, Qiagen, Redcare Pharmacy, Siltronic, TeamViewer: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| AGOMAB THERAPEUTICS | 14,650 | 0,00 % | AgomAb Therapeutics N.V.: Agomab Announces Pricing of Initial Public Offering | ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen |
Das Unternehmen PRENETICS GLOBAL LIMITED kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +8,53 % bei einem Aktienkurs von 19,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRENETICS GLOBAL LIMITED finden Sie auf Wallstreet Online.